Physician profile
Robert Schmidt
NPI 1215913546
$27,093.33
in general payments reported to CMS, 2019-2025
50 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,138 · 2020: $1,763 · 2021: $2,043 · 2022: $2,043 · 2023: $2,146 · 2024: $2,303 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $6,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,800.00 |
| Food and Beverage | $6,306.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $12,800.00 | 2025 | M2a - Modular Head Hip System |
| Janssen Pharmaceuticals, INC | $1,339.49 | 2019-2024 | Xarelto, Spravato |
| Novo Nordisk INC | $1,302.80 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,225.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,001.58 | 2019-2025 | Vraylar, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $861.41 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $713.18 | 2019-2025 | Jardiance |
| Pfizer INC. | $680.71 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $630.99 | 2019-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $558.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $480.15 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $474.86 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $394.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $373.20 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $368.79 | 2023-2025 | Aptiom, Gemtesa |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.